Agenda


Vaccine Virtual Days
Vaccination during COVID-19:
Extraordinary challenges call for
extraordinary connections
Save the date:
29-30 June,
2020

Agenda

Day 1

29th June

13:00-21:00 (GMT+1 Belgium)

Agenda

Day 1 – 29th June	13:00-16:35 (GMT+1 Belgium)	
Session: Life course immunization Session: 215 min		
13:00-13:15	**Opening by Scientific Committee member 15'**	(Scientific Committee - TBC)
Life course immunization: sub-session 1		
	Topic	**Format**	**Moderators – Markus Knuf and Paolo Bonanni**
13:15-13:25	Life course immunization	Introduction **10'**	Paolo Bonanni and Markus Knuf
13:25-13:50	Innovative methods for vaccinations delivery	Best practice sharing: Mobile unit for pediatric vaccination **5'** Drive-through clinics **5'** Communication campaign around vaccination during pandemic **5'** Discussion + Q&A **10'**	**Chair Markus** Speakers: Mona Doss (USA) Rodney Pearce (Australia) Dr Hien Minh Nguyen (Vietnam)
13:50-13:55	**Topic Break 5'**		
13:55-14:25	Rationale for NITAG recommendations, ways of working	Round table discussion **30'** Decision making process of recommendation bodies: Different countries – different decisions	**Chair: Paolo Bonanni** Speakers: Paolo Bonanni (Italy) Thomas Weinke (Germany) (TBC) Shamez Ladhani (UK)
14:25-14:40	**Sub-session Break 15'**		
Life course immunization: sub-session 2		
	Topic	**Format**	**Moderators – Markus Knuf and Paolo Bonanni**
14:40-15:10	Maternal immunization	Round table discussion Current concepts and future directions **20'** Discussion + Q&A **10'**	**Chair: Paolo Bonanni and Markus Knuf** Speakers: Flor Munoz (USA) Elke Leuridan (Belgium)
15:10-15:15	**Topic Break 5'**		
15:15-15:45	Vaccination of older adults	Benefit of vaccination for older adults **15'** (Examples: Tdap, Flu, shingles) Older adults, how to reach? **10'** Discussion + Q&A **5'**	**Chair: Paolo Bonanni** Speakers: Jean-Pierre Michel (Switzerland) Stefania Maggi (Italy)
15:45-15:50	**Topic Break 5'**		
15:50-16:20	Vaccination of special groups	Vaccination of preterm **10'** Vaccination of special groups **10'** Discussion + Q&A **10'**	**Chair: Paolo Bonanni** Speakers: Markus Knuf (Germany) Susanna Esposito (Italy)
16:20-16:35	**Session Break 15'**		

Agenda

Day 1 – 29th June			16:35-18:30 (GMT+1 Belgium)
Session: Nonspecific vaccine effects Session: 100 min			
	Topic	**Format**	**Moderator – Marco Safadi**
16:35-16:45	Nonspecific effects of vaccines	Introduction **10'**	Marco Safadi (Brazil)
16:45-17:00	Trained immunity: a memory for innate host defense	Talk **15'**	Speakers: Mihai Netea (The Netherlands)
17:00-17:15	BCG From ecological studies to evidence from clinical trials or is there reliable data showing any impact of BCG on COVID-19 risk?	Talk **15'**	Speakers: Nigel Curtis (Australia) (TBC)
17:15-17:30	Impact of early measles vaccination on mortality and the role of memory B cells	Talk **15'**	Speakers: Federico Martinón Torres (Spain)
17:30-17:45	Impact of influenzae vaccines in respiratory infections	Talk **15'**	Speaker: Albert Osterhaus (Germany)
17:45-18:15	Discussion	Q&A **30'**	Moderator: Marco Safadi Speakers: All
18:15-18:30	**Session Break 15'**		

Agenda

Day 1 – 29th June		18:30-21:00 (GMT+1 Belgium)	
Session: Assessing Vaccine Safety and Confidence in the Covid-19 era. What needs to be done? Session: 150 min			
	Topic	**Format**	**Moderator – Steve Black**
18:30-18:35	Vaccine Safety and Confidence	Introduction **5'**	Steve Black (USA)
Vaccine Safety and Confidence: Sub-session 1			
18:35-18:50	Vaccine confidence in the age of coronavirus including impact of covid19 on vaccination programs	Talk **15'**	Speakers: Heidi Larson (UK)
18:50-19:05	HPV vaccine and vaccine confidence; what did go wrong? How can this approach inform covid19 vaccine?	Talk **15'**	Speakers: Margaret Stanley (UK)
19:05-19:15	Discussion	Q&A **10'**	Moderator: Steve Black Speakers: Heidi Larson (UK) Margaret Stanley (UK)
19:15-19:20	**Topic Break 5'**		
19:20-19:35	Will America accept a COVID19 vaccine?	Talk **15'**	Speakers: Peter Hotez (USA)
19:35-19:50	Enhanced disease. How to assess it and how to minimize risk? Considerations for covid19 vaccines development?	Talk **15'**	Speakers: Paul-Henri Lambert (Switzerland)
19:50-20:05	Vaccine assessment after vaccine introduction. How to keep the public informed?	Talk **15'**	Speakers: Miriam Sturkenboom (The Netherlands)
20:05-20:15	Discussion	Q&A **10'**	Moderator: Steve Black Speakers: Peter Hotez (USA) Paul-Henri Lambert (Switzerland) Miriam Sturkenboom (The Netherlands)
20:15-20:30	**Sub-session Break 15'**		
Vaccine Safety and Confidence: Sub-session 2			
20:30-21:00	Participants from vx developers (both presenters and new), regulators Challenges associated with covid vx development and implementation: safety, enhanced disease, upscale/production/distribution, effectiveness in the long term (boosters required?), how can we maximize vaccines confidence?	Round Table **30'**	Moderator: Steve Black Speakers: David Salisbury (UK) Heidi Larson (UK) (TBC) Hanneke Schuitemaker (The Netherlands) (TBC) Thomas Breuer (GSK)

Agenda

Day 2

30th June

14:00-21:45 (GMT+1 Belgium)

Agenda

Day 2 – 30th June		14:00-16:30 (GMT+1 Belgium)	
Session: Respiratory pathogens: focus on SARS-CoV-2/COVID19 Session: 150 min			
	Topic	**Format**	**Moderator – Dr. Philippe Buchy**
14:00-14:15	**Opening by Scientific Committee member 15'**		(Scientific Committee - TBC)
14:15-14:30	**Immune response to SARS-CoV-2 infection: how does it compare to other respiratory pathogens?** Humoral and cellular responses to SARS-CoV-2: what we do know, what we don't know, what are the learnings from SARS-CoV and MERS-CoV studies that could be potentially be extrapolated to SARS-CoV-2?	Talk **15'**	Prof Malik Peiris (Hong-Kong)
14:30-14:35	Discussion	Q&A **5'**	Moderator: Dr. Philippe Buchy Speaker: Prof Malik Peiris (Hong-Kong)
14:35-14:50	**Pathogenesis of COVID19: is it something unique?** Immunopathogenesis of severe COVID19 cases: role of the virus, the receptor expression and the host immune response. How it impacts the way we may have to design vaccine development strategies?	Talk **15'**	Speakers: Prof Malik Peiris (Hong-Kong)
14:50-14:55	Discussion	Q&A **5'**	Moderator: Dr. Philippe Buchy Speakers: Prof Malik Peiris (Hong-Kong)
14:55-15:00	**Topic Break 5'**		
15:00-15:15	**Clinical features of COVID19: from asymptomatic infection to deadly disease** Spectrum of disease with focus on severe cases Clinical features more specifically/frequently observed with COVID19 compared to SARS, MERS, other severe respiratory diseases (e.g., anosmia/dysgeusia, digestive symptoms, etc.); Kawasaki-like disease in children?	Talk **15'**	Speakers: Prof David Hui (Hong-Kong)
15:15-15:20	Discussion	Q&A **5'**	Moderator: Dr. Philippe Buchy Speakers: Prof David Hui (Hong-Kong)
15:20-15:35	**New therapeutic strategies for COVID19: what are the challenges?** Antivirals, immunomodulators, plasmatherapy, etc.: the proven and the unproven	Talk **15'**	Speakers: Prof David Hui (Hong-Kong)
15:35-15:40	Discussion	Q&A **5'**	Moderator: Dr. Philippe Buchy Speakers: Prof David Hui (Hong-Kong)
15:40-15:45	**Topic Break**		
15:45-16:15	**The known unknown and the unknown known**	Round table discussion **30'** Q&A	Moderator: Dr. Philippe Buchy Speakers: Prof Malik Peiris (Hong-Kong) Prof David Hui (Hong-Kong)
16:15-16:30	**Session Break 15'**		

Agenda

Day 2 – 30th June		16:30-19:25 (GMT+1 Belgium)		
Session: Vaccine Development Session: 175 min				
	Topic	**Format**	**Moderators – Stanley Plotkin & Albert Osterhaus**	
16:30-16:35	Vaccine development	Introduction **5'**	Stanley Plotkin or Albert Osterhaus	
Vaccine Development: Sub-session 1				
16:35-16:55	**Overview general vaccine development:** Preclinical/clinical/PM Regulatory considerations in evaluating vaccine safety and efficacy	General vaccine development (1) **10'** General vaccine development (2) **10'**	Speakers: Bart Haagmans (The Netherlands) Philip Krause (USA)	
16:55-17:05	Discussion	Q&A **10'**	Moderator: Stanley Plotkin	Speakers: Speakers: Bart Haagmans (The Netherlands) Philip Krause (USA)
17:05-17:35	**Traditional technology platforms:** Live attenuated, inactivated Polysaccharide conjugate Subunits - recombinant proteins and VLPs	Traditional technology platforms (1) **10'** Traditional technology platforms (2) **10'** Traditional technology platforms (3) **10'**	Speakers: Stanley Plotkin (USA) George Siber (USA) Berend-Jan Bosch (The Netherlands)	
17:35-17:45	Discussion	Q&A **10'**	Moderator: Albert Osterhaus	Speakers: George Siber (USA) Berend-Jan Bosch (The Netherlands)
17:45-18:00	**Sub-session Break 15'**			
Vaccine Development: Sub-session 2				
18:00-18:20	**Newer technology platforms:** Reverse vaccinology/structural vaccinology Adjuvants	Newer technology (1) **10'** Newer technology (2) **10'**	Speakers: Rino Rappuoli (GSK) Thomas Breuer (GSK)	
18:20-18:30	Discussion	Q&A **10'**	Moderator: Albert Osterhaus	Speakers: Rino Rappuoli (GSK) Thomas Breuer (GSK)
18:30-19:00	**Emerging technology platforms** Nucleic acid – DNA Nucleic acid – RNA Vectors	Emerging platforms (1) **10'** Emerging platforms (2) **10'** Emerging platforms (3) **10'**	Speakers: David Weiner (USA) Drew Weisman (USA) Hanneke Schuitemaker (USA)	
19:00-19:10	Discussion	Q&A **10'**	Moderator: Stanley Plotkin	Speakers: David Weiner (USA) Drew Weisman (USA) Hanneke Schuitemaker (USA)
19:10-19:25	**Session Break 15'**			

Agenda

Day 2 – 30th June			19:25-21:45 (GMT+1 Belgium)
Session: Antimicrobial Resistance Session: 150 min			
	Topic	**Format**	**Moderator – Ian Feavers**
19:25-19:30	Antimicrobial Resistance	Introduction **5'**	Ian Feavers
Antimicrobial Resistance: Sub-session 1			
19:30-19:45	Outline of the AMR problem	Talk **10'** + Q&A **5'**	Speaker: Jim O'Neill (UK)
19:45-20:00	Antibiotics and evolution	Talk **10'** + Q&A **5'**	Speakers: Gordon Dougan (UK)
20:00-20:15	The role and advantages of vaccines in reducing AMR	Talk **10'** + Q&A **5'**	Speaker: Rino Rappuoli (GSK)
20:15-20:30	Role of biological standards in reducing AMR	Talk **10'** + Q&A **5'**	Speakers: Ian Feavers (TBC)
20:30-20:45	**Sub-session Break 15'**		
Antimicrobial Resistance: Sub-session 2			
20:45-21:45	**Vaccine pipelines** Enterics (Shigella, *E.coli*, NT-Salmonella) Progresses on Gonococcal vaccines Progresses on TB vaccines Progresses on Malaria vaccines	 Talk **10'** + Q&A **5'** Talk **10'** + Q&A **5'** Talk **10'** + Q&A **5'** Talk **10'** + Q&A **5'**	Speakers: Calman MacLennan (UK) Kate Seib (Australia) Ann Ginsberg (USA) Dr. Ashly Birkett (USA)